Good News for Australian Patients with DLBCL and MCL
We are thrilled to share some very positive news for patients across Australia living with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
Thanks to the results of recent phase III clinical trials—to which our team made significant contributions—two important treatment advances are now a step closer to becoming widely available:
-
Glofitamab + GemOx (2L+ DLBCL)
-
Acalabrutinib + bendamustine/rituximab (1L MCL)
Both regimens have received positive recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC) and are expected to be listed on the Pharmaceutical Benefits Scheme (PBS) in the near future.
This milestone is a testament to the outstanding work of our entire team—especially our clinical trials unit and fellows—whose dedication and expertise have helped make these novel therapies accessible to patients nationwide.
Together, we can be proud of the role we’ve played in improving outcomes for Australians with blood cancers and in bringing world-class treatments closer to those who need them most.